Davenport & Co’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-77,243
Closed -$7.14M 781
2019
Q3
$7.14M Sell
77,243
-401
-0.5% -$38.1K 0.09% 135
2019
Q2
$7.18M Sell
77,644
-7,811
-9% -$742K 0.09% 132
2019
Q1
$8.06M Sell
85,455
-3,893
-4% -$340K 0.1% 125
2018
Q4
$5.73M Sell
89,348
-37,856
-30% -$2.79M 0.08% 145
2018
Q3
$11.4M Sell
127,204
-6,206
-5% -$548K 0.13% 119
2018
Q2
$10.6M Buy
133,410
+3,245
+2% +$269K 0.13% 118
2018
Q1
$11.6M Sell
130,165
-470,334
-78% -$45.2M 0.14% 114
2017
Q4
$62.7M Buy
600,499
+33,294
+6% +$3.76M 0.75% 38
2017
Q3
$82.7M Buy
567,205
+1,624
+0.3% +$221K 1.05% 20
2017
Q2
$73.5M Buy
565,581
+14,701
+3% +$1.8M 0.97% 22
2017
Q1
$64.5M Sell
550,880
-3,262
-0.6% -$390K 0.92% 25
2016
Q4
$64.1M Buy
554,142
+12,639
+2% +$1.41M 0.92% 24
2016
Q3
$56.6M Sell
541,503
-2,582
-0.5% -$279K 0.83% 32
2016
Q2
$53.7M Sell
544,085
-21,776
-4% -$2.25M 0.82% 35
2016
Q1
$56.6M Buy
565,861
+8,892
+2% +$916K 0.89% 31
2015
Q4
$66.7M Buy
556,969
+3,471
+0.6% +$402K 1.08% 25
2015
Q3
$59.9M Buy
553,498
+362
+0.1% +$44.9K 1.01% 26
2015
Q2
$64M Buy
553,136
+180
+0% +$20.6K 0.99% 24
2015
Q1
$63.7M Sell
552,956
-103,866
-16% -$12.4M 0.98% 26
2014
Q4
$73.5M Buy
656,822
+2,681
+0.4% +$283K 1.19% 15
2014
Q3
$62M Buy
654,141
+5,224
+0.8% +$471K 1.08% 23
2014
Q2
$55.7M Buy
648,917
+161,369
+33% +$12.3M 0.95% 29
2014
Q1
$34M Sell
487,548
-17,570
-3% -$1.39M 0.62% 60
2013
Q4
$42.7M Buy
505,118
+2,340
+0.5% +$185K 0.8% 42
2013
Q3
$38.7M Buy
502,778
+19,094
+4% +$1.34M 0.8% 43
2013
Q2
$28.3M Buy
+483,684
New +$29.1M 0.62% 64

Other funds holding CELG

Davenport & Co's CELG Position: Q4 2019 in Review

Davenport & Co sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 77,243 shares — an estimated $7.14M sold.

Davenport & Co first reported a position in CELG in Q2 2013 and held it in 26 quarters. The position peaked at $82.7M in Q3 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Davenport & Co reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Davenport & Co sold 77,243 Celgene Corp shares in Q4 2019, an estimated $7.14M.
  • Davenport & Co first reported a position in Celgene Corp in Q2 2013 and held it in 26 quarters.
  • Davenport & Co's Celgene Corp position peaked at $82.7M in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Davenport & Co's 13F filing for Q4 2019, filed 22 Jan 2020.